Background: The prevalence of the metabolic syndrome (MetSy) steadily increases worldwide.

Aim: To evaluate the relation between the presence of MetSy and visceral obesity and the presence of coronary lesions, and to assess correlations between waist circumference and body mass index (BMI) and coronary lesions.

Methods: We studied 105 patients who underwent elective coronary angiography. The study population was divided into four groups depending on the presence of MetSy and visceral obesity. Coronary angiographic evaluation was performed by an invasive cardiologist. For ultimate objective evaluation of the degree of coronary stenoses, quantitative coronary angiography was performed. Based upon coronary angiography results, patients were divided into four groups depending on the severity of coronary artery disease (CAD): with no coronary lesions, with haemodynamically insignificant lesions (1-69% stenosis), with haemodynamically significant lesions (> 70%) in 1 or 2 vessels, and with multivessel disease (> 70% stenoses in 3 vessels or a > 50% stenosis in the left main coronary artery).

Results: Normal coronary arteries were significantly more commonly found in patients without obesity and MetSy (50% of patients). Haemodynamically significant lesions were most frequently found among obese patients with MetSy (40% of patients) and among obese patients without MetSy (38.1% of patients). Concomitant presence of obesity among patients with MetSy (i.e., MetSy with obesity as compared to MetSy without obesity) was not found to be significantly related to the severity of CAD. In addition, advanced CAD was significantly more frequent in obese patients with MetSy compared to the other groups. Isolated visceral obesity in patients without MetSy (i.e., obese patients without MetSy as compared to non-obese patients without MetSy) was found to correlate with haemodynamically significant coronary lesions. When we evaluated nonparametric correlations between waist circumference, BMI; and the severity of CAD, BMI did not correlate with coronary lesions (r = 0.08, p = 0.37). In contrast, a significant correlation was found between waist circumference and the severity of CAD (r = 0.55, p < 0.001). Haemodynamically significant lesions were more significantly more frequent in patients with MetSy compared to patients without MetSy (76% vs. 24%, p < 0.001). Haemodynamically significant lesions were found in 67.7% of patients with isolated visceral obesity compared to 23.2% of non-obese patients without MetSy. In multivariate analysis, CAD was significantly more likely among patients with MetSy regardless of the analysed model (OR 5.3, 95% CI 1.1-25.8, p < 0.05).

Conclusions: 1. The presence of MetSy significantly correlates with haemodynamically significant coronary lesions. 2. The degree of visceral obesity significantly correlates with the severity of CAD. 3. BMI does not correlate with the severity of CAD. 4. Isolated visceral obesity is a weaker determinant of haemodynamically significant coronary lesions compared to MetSy with associated obesity. 5. MetSy is associated with significantly more advanced coronary lesions, i.e. multivessel disease.

Download full-text PDF

Source
http://dx.doi.org/10.5603/kp.2013.0229DOI Listing

Publication Analysis

Top Keywords

patients metsy
44
visceral obesity
28
coronary lesions
28
metsy
20
severity cad
20
coronary
18
patients
18
coronary angiography
16
haemodynamically lesions
16
obese patients
16

Similar Publications

Introduction: Immune checkpoint blockers (ICBs) revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC) but only a fraction of them obtain a response, and clinical benefit from these treatments is often difficult to predict. The aim of our study is to unveil the potential implications of antibody response to previous viral infections in predicting response to ICBs in patients with NSCLC.

Methods: Sera from patients treated with ICBs alone, chemotherapy (CT) or a combination of CT-ICBs were analyzed with VirScan (CDI Labs, USA), a high-throughput method that comprehensively analyzes epitope-level antiviral IgG antibodies via programmable phage display and immunoprecipitation sequencing.

View Article and Find Full Text PDF

Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance.

Mol Cancer

September 2024

Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Equipe labellisée par la Ligue contre le cancer, Inserm U1138, Paris, France.

Article Synopsis
  • Higher plasma levels of ACBP/DBI, linked to age and obesity, are associated with an increased risk of cancer, especially in patients with genetic predispositions like BRCA1/2 or TP53 mutations.
  • In studies, elevated ACBP/DBI levels were predictive of future cancer development, particularly lung cancer, while neutralization of ACBP/DBI slowed tumor growth and enhanced the effects of chemoimmunotherapy in animal models.
  • The research suggests that ACBP/DBI functions as an immune suppressor and indicates that targeting it may improve cancer immunotherapy outcomes.
View Article and Find Full Text PDF

Background: Metabolic syndrome (MetSy) is characterized by the presence of obesity, hypertension, altered glucose metabolism, and/or increased non-HDL cholesterol. This study aimed at elucidating the association between obesity with subclinical target organ damage and biochemical parameters included in MetSy pathogenesis.

Methods: This study included 130 apparently healthy subjects.

View Article and Find Full Text PDF

Background: Diabetes mellitus (DM) long-term macrovascular and microvascular complications pose significant health risks and increase mortality. In DM patients, metabolic syndrome (MetSy) either precedes or coexists with the condition. Central obesity, poor glycemic control, hypertension, elevated triglycerides (TG), and low high-density lipoproteins (HDL-C) are the components of MetSy.

View Article and Find Full Text PDF

Background Major depressive disorder (MDD) is a debilitating mood disorder that increases the risk of metabolic syndrome (MS), emphasizing the need for mental and physical health treatments. Although many studies have linked atypical antipsychotics to metabolic disturbances, there is limited evidence linking selective serotonin reuptake inhibitor use to MS. This study aimed to assess the risk of MS among patients with MDD who were administered vortioxetine and fluoxetine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!